Silk Road Medical (Nasdaq:SILK) announced today that it launched its tapered EnRoute transcarotid stent system in the U.S.
Sunnyvale, California-based Silk Road says this expands upon the prior launch of its EnRoute system by adding additional configurations. It better tailors the transcarotid artery revascularization (TCAR) procedure to the patient anatomy. TCAR, a minimally invasive procedure, provides stroke protection while minimizing adverse events.
According to a news release, EnRoute marks the only commercially available transcarotid stent system indicated for patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA).
Silk Road Medical designed EnRoute with an optimized cell design. This balances lesion coverage and anatomical conformability for long-term plaque stabilization. The company made it purpose-built for TCAR with a short delivery system for ergonomic and precise stent delivery.
Dr. Joseph V. Lombardi of Cooper University Health Care called the system “a welcome addition” to his TCAR toolkit. Lombardi, Cooper’s chief of vascular surgery, said it further differentiates the company’s core product offering. Additionally, he said he now has more options to customize treatment to each patient’s anatomy.
“As pioneers in stroke prevention, our product development efforts are focused on extending our lead in the minimally invasive treatment of carotid artery disease,” said Chas McKhann, CEO of Silk Road Medical. “New tapered configurations for our EnRoute transcarotid stent system build upon the robust portfolio of Silk Road’s carotid solutions.”
McKhann labeled the company “pleased” to bring the portfolio expansion to the market. He said it marks the company’s commitment to offering a diverse toolkit for physicians.